Aromatase inhibitors and bisphosphonates reduce deaths from breast cancer, studies showBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4036 (Published 24 July 2015) Cite this as: BMJ 2015;351:h4036
- Zosia Kmietowicz
- 1The BMJ
Aromatase inhibitors and bisphosphonates can extend the lives of women with breast cancer, studies published in the Lancet have shown.
Aromatase inhibitors were already known to reduce the risk of recurrence of breast cancer more effectively than tamoxifen, but the effect on survival was unknown. To investigate this researchers from the Early Breast Cancer Trialists’ Collaborative Group combined the results of nine clinical trials including 31 920 women who had used aromatase inhibitors and tamoxifen at various times during the course of treatment. All of the women were postmenopausal and had been treated for oestrogen positive breast cancer.
Overall the results showed that women’s breast cancer was less likely to recur if they took an aromatase inhibitor (relative risk …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial